Surrogate end point evaluation has received a lot of attention for approximately a quarter of a century. Throughout this time, the topic has been surrounded with both hopes and perils ... history of the evaluation of…
Corneal confocal microscopy (CCM), a non-invasive ophthalmic technique may act as an imaging end point for neurodegeneration in patients with mild cognitive impairment (MCI) and dementia ... physical disability (P=0.03-…
maintaining exercise capacity, quality of life (QOL) and survival in PAH, but current clinical end points are limited in their predictive ability to reduce the latency in time to clinical ... report. This goal requires…
clinical trial efficacy end-points; (3) regulatory view on use of biomarkers and surrogate end-points in marketing authorisation submissions; and (4) considerations for rare diseases conditional marketing authorisations
perspective will discuss some key issues in clinical trials including a preservation, surrogate and composite end points and spin reporting. In addition, current quality rating scales and a reporting guide
decision for further development and thereby helping to minimize phase II attrition. Surrogate end points, in addition to tumor markers, add more confidence to overall trial success. Circulating markers
decision for further development and thereby helping to minimize phase II attrition. Surrogate end points, in addition to tumor markers, add more confidence to overall trial success. Despite this, there ... oncology…
purpose basis to rigorously validated assays when a biomarker is used as a surrogate end point, for patient selection, or for randomization into diff erent arms. Assay validation is essential
early vascular ageing (EVA) concept, namely: the validation of tissue biomarkers as surrogate end points for CV risk reduction; the determination of the predictive value of various of these arterial
testing include the development and validation of biomarkers that can be used as surrogate end points to reliably predict long-term clinical outcomes in Phase II and III trials, designing
natural history of PSC is often assessed through a variety of clinical and histological end points. However, none of the therapeutic options examined in clinical trials for PSC to date ... recommendations on future…
mortality. Different extents of ST segment resolution may serve as a sensitive surrogate end point in clinical trials. This finding therefore establishes a direct correlation between ST resolution
investigator-initiated trial, to implement central laboratories for outcome measures, to move new surrogate end points forward and to facilitate quality within the network through providing a quality-improvement program
primary endpoint for the patients with advanced or metastatic cancer. Before a surrogate end point can replace a so-called 'true' end point of interest, it must be formally validated
strongest prognostic parameter, guides treatment decisions and can be used as a surrogate end point in clinical trials. Molecular based methods: In lymphoid malignancies, the concept of MRD detection relies
hope that biomarkers will help diagnose symptomatic and presymptomatic disease or provide surrogate end-points to demonstrate clinical efficacy of new treatments, such as neuroprotective therapies, and help stratify this
drug targets • Late-stage failures • Complexity in clinical trial design End point studies having surrogate markers are the pivotal for the cardiovascular drug development. Innovative technology, web based conduct
vascular noninvasive imaging tools have advanced the development and validation of surrogate or intermediate end points of these chronic disorders. This article provides a review of emerging and established imaging
drugs. Current development challenges such as the design of pharmacodynamic (indicative or surrogate biomarker) and ‘hard’ end point studies are reviewed. The reader can also expect to learn about advanced
Current regulations require conducting clinical end point trials for demonstrating bioequivalence (BE) between topical generic and refernce listed drug (RLD) products. A variety of surrogate methods have been explored
there are multiple acceptable study end points that afford quantification of therapeutic impact, including quality of life, in the absence of a need for surrogate or biomarkers. Limitations
For authors and organisers
Publish, present and keep up with your field
Find the right journal for your paper and submit your manuscript.